TLIS vs. ASTC, SMIT, TBIO, SPEC, THMO, HTGMQ, OLITW, PRENW, QSIAW, and SMAPW
Should you be buying Talis Biomedical stock or one of its competitors? The main competitors of Talis Biomedical include Astrotech (ASTC), Schmitt Industries (SMIT), Telesis Bio (TBIO), Spectaire (SPEC), ThermoGenesis (THMO), HTG Molecular Diagnostics (HTGMQ), OmniLit Acquisition (OLITW), Prenetics Global (PRENW), Quantum-Si (QSIAW), and SportsMap Tech Acquisition (SMAPW). These companies are all part of the "measuring and control equipment" industry.
Talis Biomedical vs. Its Competitors
Talis Biomedical (NASDAQ:TLIS) and Astrotech (NASDAQ:ASTC) are both small-cap measuring and control equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.
In the previous week, Talis Biomedical had 1 more articles in the media than Astrotech. MarketBeat recorded 1 mentions for Talis Biomedical and 0 mentions for Astrotech. Talis Biomedical's average media sentiment score of 0.00 equaled Astrotech'saverage media sentiment score.
Talis Biomedical has a net margin of 0.00% compared to Astrotech's net margin of -1,536.99%. Astrotech's return on equity of -46.37% beat Talis Biomedical's return on equity.
43.8% of Talis Biomedical shares are held by institutional investors. Comparatively, 24.4% of Astrotech shares are held by institutional investors. 46.0% of Talis Biomedical shares are held by company insiders. Comparatively, 14.9% of Astrotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Talis Biomedical has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Comparatively, Astrotech has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500.
Astrotech has higher revenue and earnings than Talis Biomedical. Astrotech is trading at a lower price-to-earnings ratio than Talis Biomedical, indicating that it is currently the more affordable of the two stocks.
Summary
Talis Biomedical beats Astrotech on 7 of the 12 factors compared between the two stocks.
Get Talis Biomedical News Delivered to You Automatically
Sign up to receive the latest news and ratings for TLIS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TLIS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Talis Biomedical Competitors List
Related Companies and Tools
This page (NASDAQ:TLIS) was last updated on 9/6/2025 by MarketBeat.com Staff
Free TLIS Stock Alerts